San Francisco, CA, August 24, 2018 – MBC BioLabs, the premier Bay Area life-science incubator, will present its Golden Ticket programs this year as well as future initiatives at MBC BioLabs through a sponsorship from Celgene.

The Golden Ticket program is provided to promising, qualified entrepreneurs and offers priority admission or renewal, including rent support, for one year’s use of an MBC BioLabs bench and the MBC Fast-track core facilities. This unique offering provides state-of-the-art equipment and the runway to test hypotheses, gather data, and make important connections with the scientific and development community. Participants in this program may also have the opportunity to work with and receive mentorship from the Celgene team on drug discovery and development.

With a strong commitment to delivering innovative and life-changing medicines, Celgene focuses on the discovery, development, and commercialization of products for the treatment of cancer, immune, neurodegenerative, and other severe conditions. Many of the scientists applying and in residence at MBC BioLabs share this commitment.

MBC BioLabs will continue to add to their distinguished roster of corporate partners, advisors, and university colleagues to facilitate growth and learning opportunities and empower entrepreneurs to focus on game-changing science.

About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

About MBC BioLabs (Previously QB3@953)
MBC BioLabs provides space as small as a single bench in a fully equipped, premier shared laboratory environment. Scientist-entrepreneurs can conduct experiments immediately and at greatly reduced cost, accelerating the development and deployment of novel biotechnologies. Since the 953 Indiana St. facility opened in 2013, MBC BioLabs companies have raised over $1.8 billion dollars to deliver groundbreaking therapies, discovery tools, and services to markets hungry for innovation.